Relief Therapeutics Holding Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Relief Therapeutics Holding.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 42.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth
Oct 09
Relief Therapeutics Holding SA's (VTX:RLF) Share Price Boosted 52% But Its Business Prospects Need A Lift Too
Sep 03Relief Therapeutics Holding SA (VTX:RLF) Surges 52% Yet Its Low P/S Is No Reason For Excitement
Sep 03Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?
May 05Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?
Oct 04Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?
Apr 23Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?
Sep 25We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide
Jan 13In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Relief Therapeutics Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 9 | -46 | -2 | -10 | N/A |
| 3/31/2024 | 7 | -72 | -5 | -14 | N/A |
| 12/31/2023 | 6 | -98 | -9 | -18 | N/A |
| 9/30/2023 | 6 | -89 | -15 | -19 | N/A |
| 6/30/2023 | 6 | -81 | -20 | -20 | N/A |
| 3/31/2023 | 6 | -66 | -23 | -22 | N/A |
| 12/31/2022 | 6 | -51 | -25 | -24 | N/A |
| 9/30/2022 | 6 | -49 | -29 | -28 | N/A |
| 6/30/2022 | 7 | -47 | -33 | -33 | N/A |
| 3/31/2022 | 5 | -41 | -41 | -34 | N/A |
| 12/31/2021 | 3 | -35 | -49 | -36 | N/A |
| 9/30/2021 | 2 | -33 | -48 | -34 | N/A |
| 6/30/2021 | N/A | -31 | -46 | -33 | N/A |
| 3/31/2021 | N/A | -19 | -32 | -26 | N/A |
| 12/31/2020 | N/A | -8 | -18 | -18 | N/A |
| 9/30/2020 | N/A | -3 | -11 | -11 | N/A |
| 6/30/2020 | N/A | 1 | -3 | -3 | N/A |
| 3/31/2020 | N/A | -3 | -2 | -2 | N/A |
| 12/31/2019 | N/A | -7 | -1 | -1 | N/A |
| 9/30/2019 | 0 | -4 | -1 | -1 | N/A |
| 6/30/2019 | 1 | -1 | -1 | -1 | N/A |
| 3/31/2019 | 1 | -1 | -1 | -1 | N/A |
| 12/31/2018 | 1 | 0 | -1 | -1 | N/A |
| 9/30/2018 | 0 | -1 | -1 | -1 | N/A |
| 6/30/2018 | N/A | -2 | -1 | -1 | N/A |
| 3/31/2018 | N/A | -3 | N/A | -1 | N/A |
| 12/31/2017 | N/A | -3 | N/A | -1 | N/A |
| 9/30/2017 | 0 | -10 | N/A | -2 | N/A |
| 6/30/2017 | 0 | -18 | N/A | -3 | N/A |
| 3/31/2017 | 0 | -17 | N/A | -3 | N/A |
| 12/31/2016 | 0 | -17 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RLF's forecast earnings growth is above the savings rate (0.3%).
Earnings vs Market: Insufficient data to determine if RLF's earnings are forecast to grow faster than the Swiss market
High Growth Earnings: Insufficient data to determine if RLF's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if RLF's revenue is forecast to grow faster than the Swiss market.
High Growth Revenue: Insufficient data to determine if RLF's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RLF's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:11 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Relief Therapeutics Holding SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexandre Müller | Research Dynamics |
| Bob Pooler | ValuationLAB AG |